Morria Biopharmaceuticals Plc Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug
Published: Aug 25, 2009
LONDON--(BUSINESS WIRE)--Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6. The double-blind, placebo-controlled study on 80 contact dermatitis patients will take place at the Hadassah Hospital in Israel. A previous pilot clinical study demonstrated that a topical preparation of MRX6, applied for 28 days (b.i.d), scored 69% improvement based on conventional Physician’s Assessment. The upcoming study will examine a 21 days (b.i.d) regime and monitor pharmacokinetics and dose-response parameters.